<DOC>
	<DOC>NCT01130961</DOC>
	<brief_summary>The purpose of this study is to determine progression-free survival of lung cancer patients who received gefitinib in clinical practice in Thailand.</brief_summary>
	<brief_title>Management of Advanced Non-Small Cell Lung Cancer (NSCLC) and Clinical Outcomes in Patients Who Received Gefitinib in Thailand</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Diagnosed as having lung cancer based on histological/cytological findings Admitted to the hospital between January 2004 and December 2008 Treated with gefitinib for at least 3 months Involvement in the planning and/or conduct of the study Participation in another clinical study during the last 3 months</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Advanced NSCLC</keyword>
	<keyword>Gefitinib</keyword>
	<keyword>Thai patient</keyword>
</DOC>